# A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Study · id `cardio:ct-nct07660796` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07660796](<https://clinicaltrials.gov/study/NCT07660796>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07660796

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 256 participants.

## Technical summary

Registry record NCT07660796. Randomized; double masking; primary purpose treatment. Start 2026-07-06 (anticipated); primary completion 2027-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 256 participants (planned count; ClinicalTrials.gov record NCT07660796, source copy `cardio:ctgov-nct07660796-2026-06-30`, retrieved 2026-10-26)
- Planned start: 2026-07-06 (anticipated) (ClinicalTrials.gov record NCT07660796, source copy `cardio:ctgov-nct07660796-2026-06-30`, retrieved 2026-10-26)
- Primary completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT07660796, source copy `cardio:ctgov-nct07660796-2026-06-30`, retrieved 2026-10-26)
- Completion: 2027-11-30 (anticipated) (ClinicalTrials.gov record NCT07660796, source copy `cardio:ctgov-nct07660796-2026-06-30`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07660796, source copy `cardio:ctgov-nct07660796-2026-06-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07660796-2026-06-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): HCP1803-3
- Intervention (Drug): HCP1803-4
- Intervention (Drug): RLD2001-1
- Intervention (Drug): RLD2001-2
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 7b7f55290f70dc8960549dfdcf036be44f9f9f3351efc14b006a636b00b31817
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
